The group of Dr. Ayal Hendel works on the improvement of the CRISPR-Cas9 genome editing technology as a mean of genetic disorder therapy, by increasing the robustness and specificity of the method, to allow its use in clinical settings. His team primarily focuses on correcting mutations in hematopoietic genetic disorders as well as on improving the current immune therapies for fighting cancer through modification of T-cell receptors.

Group website